News


3/28/19 - Kaneka Pharma America LLC in the News


Kaneka Pharma America is pleased to announce that the FDA approved the modification of the indications for the use (IFU) of Kaneka’s LIPOSORBER® LA-15 system. This approval will allow more US patients to use our apheresis treatment to lower low-density lipoprotein cholesterol (LDL-C) levels. The FDA made the following modification:
The LDL-C cut-off in Group C is now reduced to 100 mg/dL from 160 mg/dL.

The LIPOSORBER IFU as of March 28, 2019:
The LIPOSORBER LA-15 System is indicated for use in performing low density lipoprotein cholesterol (LDL-C) apheresis to acutely remove LDL-C from the plasma of the following high-risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated:

  • Group A – Functional Hypercholesterolemic Homozygotes with LDL-C >500 mg/dL;
  • Group B – Functional Hypercholesterolemic Heterozygotes with LDL-C ≥300 mg/dL; and
  • Group C – Functional Hypercholesterolemic Heterozygotes with LDL-C ≥100 mg/dL and either documented coronary artery disease or documented peripheral artery disease.

In accordance with FDA requirements, Kaneka will revise our labeling to reflect the approved new indications for use. While we make those updates, this new indication is effective as of March 28, 2019. Attached is the FDA’s approval letter for more information. Kaneka believes this development will assist physicians in their treatment plans for patients with severe hypercholesterolemia. If you have any questions, please contact us at 612-590-9446.

Sincerely,
Naoto Oyama
President, Kaneka Pharma America LLC

Read the FDA Letter

Therapy Areas

Mission


To contribute to human well-being through the application of biomedical engineering in the research, design, and sale of devices that promote health.

Kaneka Pharma America is committed to:

  • Providing safe, high-quality, and user-friendly products
  • Reducing the burden of illness on patients, families and caregivers
  • Driving the standard of care by contributing to evidence-based medicine (EBM) with published, peer-reviewed literature
  • Collaborating with Healthcare Providers in developing new product ideas and improving existing products
  • Ensuring accountability, fairness and transparency in accordance with Kaneka’s Governance and Compliance standards

Location

Kaneka Pharma Americe US Locations Map

Kaneka Pharma America LLC


546 5th Avenue, 21st floor
New York, NY 10036

Phone: 212-705-4340
Hours: Monday-Friday 9AM to 5PM EST


History

Kaneka Pharm America History Timeline

Kaneka Group

Leveraging Our Science to Make Wishes Come True, All Around the World